Supplementation of a dairy drink enriched with milk phospholipids in patients with atopic dermatitis - a double-blind, placebo-controlled, randomized, cross-over study.

Sylvia Keller, Hai-Yen Le, Christiane Rödiger, Uta-Christina Hipler, Romy Kertscher, Angelika Malarski, Lisa-Marie Hunstock, Michael Kiehntopf, Martin Kaatz, Johannes Norgauer, Gerhard Jahreis

Journal: Clinical nutrition (Edinburgh, Scotland) 2015;33(6):1010-6

PMID: 24559855

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND & AIMS

Reduced epidermal ceramide content may lead to an impaired skin barrier in atopic dermatitis. Plasma concentration of the ceramide precursor sphingomyelin increases after milk-fat consumption due to affected lipoprotein metabolism, although sphingomyelin, a main component of milk phospholipids, might also directly influence plasma sphingomyelin levels. The aim was to determine whether supplementation of a dairy drink with milk phospholipids improves skin parameters and influences plasma lipid profile.

METHODS

In a double-blind cross-over study, 39 patients were randomized into 2 groups and daily received phospholipid milk (3 g phospholipids ≙ 0.75 g sphingomyelin) or normal whole milk as placebo control for 6 weeks. SCORAD indices, serum immune and plasma lipid parameters were determined.

RESULTS

SCORAD indices did not differ between groups following control and phospholipid milk supplementation (control milk: 10.9 ± 5.9 vs. phospholipid milk: 11.7 ± 6.9, P = 0.416), but were significantly decreased compared to baseline (baseline: 15.6 ± 8.8, P < 0.05). Plasma sphingomyelin proportions were also similar after the treatments (control milk: 27.5 ± 2.3 vs. phospholipid milk: 27.4 ± 2.6% of total phospholipids, P = 0.894), but were significantly increased compared to baseline (20.7 ± 2.4% of total phospholipids, P < 0.05).

CONCLUSIONS

Supplementation of a dairy drink with milk phospholipids has no beneficial effect on skin parameters compared to consumption of whole milk in patients with atopic dermatitis. To elucidate an impact of the plasma sphingomyelin proportion on skin conditions, further studies are necessary. Clinical trial ID: Registered under ClinicalTrials.gov. Identifier no. NCT01326520.

Address: Friedrich Schiller University of Jena, Department of Nutritional Physiology, Dornburger Straße 24, D-07743 Jena, Germany. Electronic address: [email protected].; Friedrich Schiller University of Jena, Department of Nutritional Physiology, Dornburger Straße 24, D-07743 Jena, Germany.; University Hospital of the Friedrich Schiller University of Jena, Department of Dermatology, Erfurter Straße 35, D-07740 Jena, Germany.; University Hospital of the Friedrich Schiller University of Jena, Institute of Clinical Chemistry and Laboratory Medicine, Erlanger Allee 101, D-07747 Jena, Germany.; SRH Wald-Klinikum Gera, Department of Dermatology and Allergology, Straße des Friedens 122, D-07548 Gera, Germany.

DOI: 10.1016/j.clnu.2014.01.014

Link outs

Free resources

Medical:

https://clinicaltrials.gov/search?term=AREA%5BRefe...

Other Literature Sources:

https://scite.ai/reports/24559855

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, C-Reactive Protein, Chemokine CCL22, Cholesterol, HDL, Cholesterol, LDL, Cross-Over Studies, Dairy Products, Dermatitis, Atopic, Double-Blind Method, E-Selectin, Female, Food, Fortified, Humans, Immunoglobulin E, Interleukin-16, Male, Phospholipids, Sphingomyelins, Surveys and Questionnaires, Treatment Outcome, Triglycerides, Young Adult